Elicio Therapeutics 宣布,其针对转移性 mKRAS 胰腺癌的 Eli-002 7P 疗法,联合后续的检查点抑制剂治疗,已观察到多例患者达到完全缓解。这一积极数据展现了该组合疗法在应对这一难治性癌症方面的潜力。
Elicio Therapeutics 宣布,其针对转移性 mKRAS 胰腺癌的 Eli-002 7P 疗法,联合后续的检查点抑制剂治疗,已观察到多例患者达到完全缓解。这一积极数据展现了该组合疗法在应对这一难治性癌症方面的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.